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TNF-related apoptosis-inducing ligand (TRAIL) is an important component of the immune system. Although it is well acknowl-
edged that it also has an important role in Type 1 Diabetes (T1D) development, this presumed role has not yet been clearly revealed.
Streptozotocin (STZ) and Cyclophosphamide (CY) are frequently used agents for establishment or acceleration of T1D disease in
experimental models, including the non-obese diabetic (NOD) mice. Although such disease models are very suitable for diabetes
research, diﬀerent expression patterns for various T1D-related molecules may be expected, depending on the action mechanism
of the applied agent. We accelerated diabetes in female NOD mice using STZ or CY and analyzed the expression profiles of TRAIL
ligand and receptors throughout disease development. TRAIL ligand expression followed a completely diﬀerent pattern in STZ-
versus CY-accelerated disease, displaying a prominent increase in the former, while appearing at reduced levels in the latter. Decoy
receptor 1 (DcR1) expression also increased significantly in the pancreatic islets in STZ-induced disease. Specific increases observed
in TRAIL ligand and DcR1 expressions may be part of a defensive strategy of the beta islets against the infiltrating leukocytes, while
the immune-suppressive agent CY may partly hold down this defense, contributing further to diabetes development.
1. Introduction
Type 1 diabetes (T1D) results from selective autoimmune
destruction of the pancreatic beta islets by the infiltrating
inflammatory cells [1, 2]. Among the various molecules
known to take role in the disease course, the recently
defined Tumor-necrosis factor- (TNF-) related apoptosis-
inducing ligand (TRAIL) holds a unique position. There is
evidence for both destructive and especially protective roles
for TRAIL in T1D unlike other TNF-alpha family members,
which are mainly known for destructive eﬀects on pancreatic
beta cells [3–7]. TRAIL is a type 2 membrane protein
that can interact with four diﬀerent membrane receptors
and a soluble osteoprotegerin receptor in humans. Of the
transmembrane receptors, TRAIL-R1 (DR4) and TRAIL-R2
(DR5) serve as death receptors, while they can also activate
nuclear factor NF-κB pathways [8–10]. TRAIL-R3 (DcR1)
and TRAIL-R4 (DcR2) are called decoy receptors that are
not capable of triggering apoptosis, yet may activate NF-
κB [11]. In mice, on the other hand, only three membrane
TRAIL receptors have been defined, one of which is a death
receptor and shows great homology with the human DR5
[10]. The other two are decoy receptors with no intracellular
domains.
The exact role of TRAIL and its receptors in the
development of T1D is yet to be identified. Blocking of the
TRAIL function with a soluble TRAIL receptor was shown to
accelerate diabetes in a study conducted on NOD mice [3].
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It was also presented in the same study that TRAIL-
deficient C57BL/6 mice displayed an earlier onset of diabetes
following application of multiple low doses of streptozotocin
(STZ) compared to normal mice. Results from these two
experimental patterns along with a few others suggested a
protective role for TRAIL against autoimmune inflamma-
tion. On the other hand, presence of TRAIL was reported as a
part of the T-cell response repertoire in beta cell destruction
[4]. In the mentioned study, activated T-cell lines derived
from 29 children with new-onset T1D displayed elevated
TRAIL expression in the infiltrating T cells. Our group has
also reported correlation between high TRAIL expression
levels and increased beta cell death in human pancreas
[12, 13]. Thus, there are also reports contrarily suggesting
a destructive role for TRAIL in diabetes development.
Clarification of this seemingly controversial role of TRAIL
is necessary for a thorough understanding of the disease
mechanism.
Nonobese diabetic (NOD) mice constitute very suitable
in vivo models for studies in human T1D. An important
portion of what is known today about this disease has been
provided by investigations using NOD mice. This is because
studying with human pancreatic tissue is highly constricted
due to both medical and ethical issues and also because NOD
mice represent the closest T1D model to human disease
[14]. Although NOD mice develop spontaneous diabetes,
investigators frequently use diabetes-accelerating agents for
usually a quicker presentation of disease and a higher preva-
lence [5, 15]. Streptozotocin (STZ) and cyclophosphamide
(CY) are two well-known and widely used agents for such
purpose. STZ is taken into cells via GLUT2 receptors due to
its resemblance to glucose molecule, which limits its action
primarily to the beta cells. Its toxic eﬀect is exerted through
mechanisms such as nitric oxide formation, alkylation, and
DNA fragmentation [16–18]. CY, on the other hand, is
thought to directly aﬀect (suppress) the CD4+ CD25+ T reg
cells, easing development of diabetes [19].
It is thus well accepted that while the induction/accel-
eration of diabetes provides suitable disease models, diﬀer-
ent diabetes-inducing agents usually have distinct disease-
causing mechanisms. This diﬀerence may well be reflected
as diﬀerential eﬀects on the elements of the immune system
such as the TRAIL ligand. In this study, we hypothesized that
expression levels of TRAIL ligand and its transmembrane
receptors may be distinctly influenced by STZ and CY. We
used the diabetes-prone NOD mice to test our hypothesis.
Insulitis-resistant diabetes-free nonobese diabetes resistant
(NOR) mice were used as controls, and went through the
same experimental procedures as the NOD mice. We found
that TRAIL ligand expression levels were elevated in the
pancreatic islets following STZ injection in NOD mice. In
contrast, a prominent reduction was observed following
induction with CY. DcR1 expression increased along with
TRAIL ligand in the islets in STZ-accelerated diabetes, while
no significant change was observed following CY application.
These results indicate diﬀerential eﬀects of two diﬀerent
diabetes-inducing agents on the expression profiles of TRAIL
ligand and its DcR1 receptor, while providing implications
on their roles in T1D development.
2. Materials and Methods
2.1. NOD and NOR Mice. Female NOD/LtJ (NOD) and
NOR/LtJ (NOR) mice were purchased from Jackson Lab-
oratory (Bar Harbor, Me, USA), which reached our lab at
5 weeks of age. All mice were housed at an isolated section
in the Experimental Animal Care and Production Unit
of Akdeniz University, Faculty of Medicine, with a 12 h
light-dark cycle. The mice were quarantined at the men-
tioned unit for three weeks before application of any experi-
mental procedures. All animal work was conducted under
the approval of the Institutional Animal Care and Use
Committee of Akdeniz University and in accordance with
the Helsinki Declaration guidelines. NOR mice were used to
set proper control groups for the procedures held in NOD
mice and put through exactly the same protocols.
2.2. Induction and Evaluation of Diabetes. Streptozotocin
(STZ) (Sigma-Aldrich) was prepared in citrate buﬀer solu-
tion immediately before i.p. administration to provide the
appropriate pH (4.2–4.5) for its activation. The cyclophos-
phamide (CY) (Endoxan) solution was also prepared imme-
diately before the i.p. injection, in 0.9% saline. A single dose
of STZ (150mg/kg) or CY (200mg/kg) was administered to
prediabetic (10 weeks old) female NOD mice and also to
age-matched female NOR mice. Thus, all the mice included
in this study received one of the mentioned diabetes-
accelerating agents or vehicle. Mice were tested for onset of
diabetes through measurements of nonfasting blood sugar
once every other day using blood collected from the tail
vein with a portable glucose meter (Accu-Check Go; Roche,
Nutley, NJ, USA). Mice with a blood sugar level of 250mg/dL
or over on two consecutive measurements were considered
diabetic.
2.3. Dissection of Pancreata. Pancreata were carefully isolated
from the related organs and tissues in mice under ketamine-
xylazine anesthesia and placed in 10% formalin. Mice were
immediately sacrificed afterwards. The sample collection
times after injections were as follows: days 2, 4, 7, 11, and
14 from STZ-applied NOD and NOR mice and days 1, 4, 7,
14, and 21 for CY-applied NOD and NOR mice. Pancreatic
samples from three mice were isolated at each point for NOD
mice. Two samples per point were evaluated for NOR mice
for CY application. Tissues collected from STZ-applied NOR
mice were not evaluated as control samples, as stated below,
as these mice were very severely aﬀected by STZ induction.
Pancreatic tissues were also isolated at day 0 (before agent
injection) from at least 3 other NOD and NOR mice.
2.4. Immunohistochemistry. The formalin-fixated pancreatic
tissues were paraﬃn embedded, and serial sections (4-
5 μm) were obtained from diﬀerent levels of the blocks.
Haematoxylin-eosin staining was used for general struc-
tural observation. Immunostaining was performed on
formalin-fixed, paraﬃn- wax embedded sections. Expres-
sion levels of the TRAIL ligand and its receptors were
detected with suitable rabbit anti-mouse primary antibodies
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(polyclonal, diluted 1 : 100, Prosci-Inc, Calif, USA). The brief
procedure is as follows: sections from each block were
deparaﬃnized and heated in a microwave oven for 10min
for antigen retrieval. Endogenous peroxidase was blocked
using 3% hydrogen peroxide in methanol for 10min. Each
incubation step was followed by thorough washing of the
slides in distilled water and phosphate-buﬀered saline (PBS)
(0.001%, Sigma). After incubation with primary antibodies
for 60min, sections were allowed to react with the secondary
biotinylated antibody (Lab Vision/Thermo Fisher Scientific)
for 15min and streptavidin peroxidase (TS-125-HR; Lab
Vision) for 15min. Finally, all slides were treated with DAB
reagent (Lab Vision/Thermo Fisher Scientific) for equal
time intervals across all samples for color development
and counterstained with Mayer’s haematoxylin. In all series,
relevant positive controls included sections from lymph
nodes. Tissue samples that were stained with the secondary
antibody alone were used as negative controls.
2.5. Immunohistochemical Scoring. A pathologist (G. O.
Elpek) who had no prior knowledge about the tissue origins
interpreted the slides for both distribution (percentage of
the positively stained cells) and intensity of immunostaining.
In each case, positive and negative cells were counted at
400x magnification and the percentage was calculated as the
number of positive cells relative to the total number of cells
counted. Intensity of staining was classified as (0) negative,
(1) weak, (2) moderate, and (3) strong for positivity in nuclei
and/or cytoplasm. Marker distribution was scored as (0) less
than 10%, (1) between 10% and 40%, (2) between 40% and
70%, and (3) for more than 70% of the cells stained positive.
The final staining score was determined as the total of the
intensity and marker distribution scores. The number of
islets evaluated ranged from 4 to 12 (mean: 8, 3±3, 7) for the
assessment of immunostaining in endocrine cells. Insulitis-
free areas were used for evaluation in the islets surrounded
with infiltrating lymphocytes.
2.6. Statistical Analysis. Statistical analysis was performed
with SPSS 13.0 for Windows (SPSS Inc. Chicago, Ill, USA).
Normality tests were carried out in the groups by Shapiro-
Wilk test. Statistical evaluation continued with Mann-
Whitney U test which allows comparison of two independent
groups, for evaluation of the statistical significance of the
diﬀerences observed. Statistical significance was considered
at 5% probability level (P < 0.05).
3. Results
3.1. Diabetes Development Was Diﬀerentially Accelerated in
NOD Mice by Single Injection of Streptozotocin (STZ) or
Cyclophosphamide (CY) at 10 Weeks of Age. Various diﬀerent
application doses of STZ have been reported in studies
conducted on NODmice applied at varying ages [20, 21]. We
applied 200mg/kg STZ as a starter dose in a small number
of animals (n = 5) as a pilot study. The mentioned dose
displayed a very fast and lethal eﬀect on the mice, where 3
out of 5 mice died at day 6 of application. We then applied
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Figure 1: Mean blood glucose levels following STZ- or CY-
inductions. NOD mice received single intraperitoneal injections of
150mg/kg STZ or 200mg/kg CY or vehicle (physiological saline or
citrate buﬀer) at 10 weeks of age. Fifteen mice were used for initial
inductions in both STZ and CY groups. Three mice were sacrificed
at each point for immunohistochemical pancreas analysis starting
from day 1 for the CY group and day 2 for the STZ group. The given
values represent the mean blood glucose values for the live subjects,
including those to be sacrificed, at each point.
a decreased dose of 150mg/kg STZ, which did not display
undesired immediate toxic eﬀects. A total of 15 female NOD
mice at 10 weeks of age were then injected with 150mg/kg
STZ. Some of the mice displayed symptoms of the disease
starting at day 4, such as blood sugar levels of over 250mg/dL
and progressive weight loss. The mean blood sugar levels
measured in NOD mice after day 4 were over 250mg/dL at
all points (Figure 1). On the other hand, CY was applied at a
single dose of 200mg/kg to 15 female NOD mice at 10 weeks
of age. These mice developed T1D at a slower course and
at a lower incidence compared to the STZ-induced animals
(Figure 1). Diabetic blood sugar levels were reached starting
from day 11. The proportions of the diabetic subjects in the
sacrificed groups at each point (n = 3) for marker evaluation
in the 150mg/kg STZ-applied and 200mg/kg CY-applied
experimental groups are presented in Table 1.
3.2. TRAIL Ligand Expression Levels Followed a Completely
Diﬀerent Pattern in the Pancreatic Islets of STZ-versus CY-
Applied Animals. Prior to the analysis of TRAIL ligand
and receptors in the pancreatic islets, immunohistochemical
stainings were performed on lymph node sections to confirm
the specificities of the antibodies used, which revealed strong
staining patterns. Incubation of the lymph node with the
secondary antibody alone (negative control), in contrast,
did not result in any positive staining. Sample lymph node
stainings for TRAIL and its DcR1 receptor are shown
(Figure 2). Diﬀerences in staining intensities between the
beta islets and the acinar cells further confirmed specificity
(Figures 3 and 4).
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Table 1: Proportions of diabetic subjects in the sacrificed groups at each point in STZ- or CY-applied NOD mice groups.
STZ group (start of diabetes: day 4) CY group (start of diabetes: day 11)
Day 2 Day 4 Day 7 Day 11 Day 14 Day 1 Day 4 Day 7 Day 14 Day 21
0/3 1/3 3/3 3/3 3/3 0/3 0/3 0/3 2/3 2/3
C TRAIL DcR1
Figure 2: Lymph node staining of the TRAIL ligand and its DcR1 decoy receptor. Specificities of the primary antibodies were confirmed
on lymph node sections. Stainings for TRAIL and DcR1 are shown. C stands for the negative control staining, where only the secondary
antibody was used in the immunohistochemical procedure.
Expression levels of TRAIL ligand and receptors in
the pancreatic sections of the subjects were detected by
immunohistochemical analysis as described in Section 2.
In NOD mice that received STZ as a diabetes-accelerating
agent, TRAIL expression displayed a statistically significant
yet temporary decrease between the second and fourth days
of injection, when at least two out of three mice sacrificed
were diabetes free (P < 0.05) (Figure 3(b)). However, TRAIL
expression levels started to increase in the following days.
The rise at day 14 was statistically significant, at a point
where all the animals followed were diabetic, compared to
expressions detected at day 0 (P < 0.05). Data that was
acquired from STZ-injected NOR mice (not shown) could
not serve as controls for the related data obtained from the
NOD mice. This is because NOR mice were very severely
aﬀected from STZ induction (see below).
Following CY application, on the other hand, TRAIL
expression was higher during at least the first four days,
compared to the basal levels detected prior to injections
(Figure 3(b)). All animals were diabetes free at this period.
We observed a reduction starting from day 7. At day 14 and
21, TRAIL expression levels were quite lower than the values
measured at day 0. The reduction at day 14 was statistically
significant (P < 0.05). Two out of three animals sacrificed at
both points were diabetic. TRAIL expression levels detected
in CY-injected NOR mice were generally lower than those of
NODmice acquired at day 0 all throughout the experimental
course (data not shown).
3.3. DcR1 Levels Increased in STZ-Applied NOD Mice Islets.
DcR1 levels increased following STZ injection (Figure 4(b)).
Interestingly, DcR1 expression was kept at a relatively low
level in the first few days at a mainly diabetes-free stage
for all the animals, somewhat similar to what was observed
for TRAIL (P < 0.05). It reached its highest levels at days
11 and 14, when all the mice were diabetic. The increase
recorded at day 14, when all the animals analyzed were
diabetic, was statistically significant. No significant change
was evident in DcR1 levels after CY application. Although
a slight increase in the DR5 and DcR2 receptor levels was
evident throughout the development of accelerated diabetes
by both agents, the increase was not statistically significant
(Figure 5).
3.4. TRAIL Decoy and Death Receptor Expressions Generally
Increased in Acinar Cells Following STZ or CY Application,
Whereas TRAIL Ligand Expression Levels Were Diﬀerentially
Aﬀected. TRAIL receptor expressions increased in the acinar
cells of the STZ- and CY-treated NOD mice, compared to
the values obtained at day 0, before application of any agents
(Figure 6). TRAIL ligand expression, on the other hand,
increased by STZ while kept at minimal levels by the action
of CY. DcR1 or TRAIL expression in the acinar cells after STZ
application did not display a temporary decrease during the
first days of application, contrary to what was observed in the
islets. While TRAIL ligand expression was already at minimal
levels in the acinar cells at day 0, it was kept at minimum all
through CY-induced disease. Sample stainings can be viewed
in Figures 3 and 4.
3.5. NOR Mice Were Aﬀected More Severely from STZ
Compared to the NOD Mice. NOR mice are described as
insulitis-resistant and diabetes-free strains and are defined
by the producer Jackson Lab as appropriate controls for
examining the role of non-MHC genes in development of
diabetes. We used 10 NOR mice each for STZ and CY
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Figure 3: Histologic examination of the pancreatic islets of STZ- or CY-treated NOD mice for TRAIL ligand expression. NOD mice received
single intraperitoneal injections of 150mg/kg STZ or 200mg/kg CY. Pancreata were isolated at days 0, 2, 4, 7, 11, and 14 in the STZ group,
and at days 0, 1, 4, 7, 14, and 21 in the CY group. Three mice were sacrificed at each point. Representative images are shown for negative,
weak, moderate, and strong stainings for the TRAIL ligand expression. (a) Sample stainings for STZ-treated mice are shown through (A)–
(D), and for CY-treated mice through (E)–(H): (A) and (E) show negative staining for TRAIL in the pancreatic islet in the STZ- and
CY-treated groups, respectively; the surrounding acinar cells display weak IC staining (arrow) in (A). Weak IC (B), moderate IC (C), and
strong nuclear (D) positivity in the pancreatic islets. Acinar cells display strong nuclear positivity in (D); (F) presents weak (thin arrow)
and moderate (thick arrow) IC stainings within the islet, (G) moderate (thin arrow) and strong (thick arrow) IC positivity in the islet, (H)
moderate IC and strong nuclear staining in majority of the islet, and moderate nuclear positivity in acinar cells. Control staining (secondary
antibody only) is shown in (I). Smaller islets are depicted at 400X magnification for clarity, while other images were taken at 200x. (b)
Immunohistochemical staining results for TRAIL were evaluated as described in Section 2. Changes at days 2, 4, and 14 observed in the
STZ group, and the alteration observed at day 14 in the CY group were statistically significant (P < 0.05). Error bars represent ±SEM. IC:
intracytoplasmic.
induction groups as controls. They received exactly the same
doses as the NOD mice. However, rather unexpectedly, STZ
had a more severe eﬀect on the diabetes-resistant NOR mice
compared to the diabetes-prone NOD mice. These mice
displayed diabetic blood sugar levels (>250mg/dL) at the
second day of STZ application. At day seven, 80% of the mice
died (Figure 7). For this reason, NOR mice could not serve
as controls for the STZ applications in NOD mice. Instead,
expression levels at day 0 of application were used as control
values. On the other hand, CY did not display any toxic
or diabetic eﬀects on NOR mice. All animals were at good
condition all throughout the experimental course following
induction, and blood sugar levels stayed under 118mg/dL at
all points (Figure 7).
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Figure 4: DcR1 expression analysis in STZ- or CY-treated NOD mice. Pancreata were isolated at days 0, 2, 4, 7, 11, and 14 in the 150mg/kg
STZ-injected group and at days 0, 1, 4, 7, 14, and 21 in the 200mg/kg CY-injected group. Representative images are shown for negative,
weak, moderate, and strong stainings for DcR1 expression. (a) Sample stainings for STZ-treated mice are displayed through (A)–(D), and
for CY-treated mice through (E)–(H): negative staining for DcR1 is shown in (A) and (E); moderate IC staining is evident in some acinar
cells in (E), depicted by arrow. (B) Weak IC positivity in the islet, moderate IC staining in the acinar cells, (C) weak IC, moderate nuclear
(thin arrow) and strong nuclear (thick arrow) staining in the islet, moderate nuclear staining in acinar cells, (D) weak IC and strong nuclear
positivity in the islet, along with strong nuclear positivity in acinar cells, (F) weak IC staining in the islet, moderate IC positivity in some
acinar cells, (G) moderate (thin arrow) and strong (thick arrow) positivity in the islet, no staining in acinar cells, (H) moderate IC, as well
as strong nuclear stainings in the islet, moderate nuclear staining in the acinar cells, (I) control staining with secondary antibody alone.
Smaller islets are depicted at 400x magnification for clarity. Other images were taken at 200x. (b) Immunohistochemical staining evaluations
for DcR1 were performed as described in Section 2. Each bar represents mean data from three mice. Increase at day 14 in the STZ group is
significant (P < 0.05). Error bars represent ±SEM. IC: intracytoplasmic.
4. Discussion
Various cytokines such as FasL and TNF-alpha have been
related to beta cell destruction in T1D. In con-trast,
controversial roles were attributed to TRAIL, which is an
important component of the immune system. Further
studies are required to clarify the exact role of TRAIL in
this disease. NOD mice are frequently used in investigations
related to T1D, and accelerated disease models provide
both a higher prevalence and a faster disease development.
STZ and CY are among the most commonly used diabetes-
inducing agents for this purpose. We hypothesized that
STZ and CY would diﬀerentially influence TRAIL ligand
and receptor expression levels due to their distinct action
mechanisms and that the related findings would provide
implications on the role of these marker molecules in T1D
development. Our results revealed that TRAIL ligand and
DcR1 expression levels were increased by the action of STZ
in the pancreatic beta cells of the NOD mice. Whether
this may suggest a possible protective role for these two
markers for the pancreatic beta cells against the heavily
infiltrating lymphocytes may be elucidated by further
supportive investigations. CY treatment, on the other
hand, led to a definite reduction in the level of TRAIL.
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Figure 5: Expression profiles for DcR2 and DR5 in STZ- or CY-applied, NOD mice. Sample collection days for immunohistochemical
analyses are given under bars. The collection days shown correspond to the common pancreata collection points in both groups. The mean
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Figure 6: TRAIL ligand and marker expressions in pancreatic acinar cells of STZ- or CY-applied NOD mice. Expression values before agent
application (day 0) and at the last pancreas collection points (Day 14 for STZ application and day 21 for CY application) are given. The
mean values of 3 diﬀerent subjects are presented in each bar. Error bars represent ±SEM. Statistical significance (∗) was determined by
Mann-Whitney U test applied following the Shapiro-Wilk normality test. A P value of 0.05 was considered significant.
Reduction in TRAIL expression in the islets in this instance
may contribute to the diabetes-accelerating action of
CY.
We aimed for an intermediate diabetes development rate
with the possible highest prevalence when deciding the STZ
and CY doses to be applied to test our hypothesis. Varying
doses of STZ and CY have been used for acceleration of
diabetes in NOD mice [5, 15, 19, 21]. Factors such as the
general health condition and age of the subjects at the time of
injection, accommodation conditions, route of application,
and possibly even slightly diﬀering yet unrecognized genetic
backgrounds may all aﬀect the survival of these subjects and
diabetes prevalence in induced disease, besides the applied
concentration. With regard to STZ treatment, it is well
known that a single high dose induces a more rapid loss of
insulin secretion and therefore more rapid onset of diabetes
in mice. We ran a pilot study with a high dose of the agent
at the start of our investigation. A single dose of 200mg/kg
STZ was severely toxic for the NOD mice (n = 5) and caused
majority of the animals to die at day 6. Yet, no prominent
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Figure 7: Survival patterns and mean blood glucose level profiles for NOR mice. (a) Mortality rates for NOR mice. Female NOR mice
received the same agent doses as the NOD mice, that is, single intraperitoneal injections of 150mg/kg STZ (n = 10), or 200mg/kg CY
(n = 10) or vehicle (physiological saline or citrate buﬀer) at 10 weeks of age. Eighty percent of the STZ-injected mice died at day 7. (b)
Changes in blood glucose levels in NOR mice. Nonfasting blood sugar levels of the STZ-, CY-, or vehicle-injected NOR mice groups were
measured by a portable glucose meter. Data are given as mean ± SEM.
or premature severe toxicity was observed at 150mg/kg
(Figure 1). Although the eﬀect of a single and relatively high
dose of STZ on the expression levels of TRAIL ligand and
receptors was detected in this study, it may be meaningful to
compare this eﬀect with that in a disease setting established
with lower and multiple doses of the agent. On the other
hand, a single dose of 200mg/kg CY treatment applied to
10 weeks old female NOD mice provided a suitable model
(Figure 1). Consistently, this dose has also been preferred in
many other reports [3, 5, 19].
In contrast to the increased expressions of TRAIL ligand
and DcR1 observed in relatively advanced disease stages in
our study (discussed below), a significant reduction was evi-
dent in the expression level of especially TRAIL both between
days 2 and 4 of STZ injection, while DcR1 levels were also
kept low (Figures 3 and 4). Diabetic symptoms (blood sugar
levels over 250mg/kg and gradual weight loss) started at day
4 in the STZ-applied NOD mice group. Activation of the
infiltrated T lymphocytes has been reported to be hindered at
early stages of diabetes in NODmice developing spontaneous
disease, by the action of an immune regulator mechanism.
Beta cells get into a temporary proliferative cycle at this
stage, possibly in an eﬀort to compensate for the damage.
Following this, a wide-ranged destruction of the beta islets
occurs with T-cell activation, most likely due to the ongoing
presence of beta cell antigens [22, 23]. Further investigation
is required to find out if this mentioned proliferative stage
at the start of diabetic symptoms is associated with the low
levels of TRAIL and DcR1 expressions detected in our study
following STZ injection.
It is well accepted that the diabetes-inducing agents
STZ and CY have diﬀerent disease-causing mechanisms.
In the immunohistochemical analysis performed following
STZ induction, a significant increase was detected in the
expression levels of the TRAIL ligand and DcR1 receptor
expressions in the pancreatic islets of NOD mice at day 14,
when all the subjects followed were diabetic, compared to
day 0 (prior to STZ injection) (Figures 3 and 4). Expre-ssion
levels of these markers may have increased in islet cells in
response to the rapid development of diabetes following STZ
injection accompanied with a heavy lymphocyte infiltration.
Increased TRAIL expression has been shown in the cytokine-
induced beta islets by Mi et al. [5]. Also, in a recent study
by our group, TRAIL overexpression was used as a strategy
to increase its expression levels in the allotransplanted beta
islets to diabetic rats, thus providing a higher protection
against the infiltrating leukocytes. We showed that high
TRAIL expression provided in the transplanted pancreatic
islets by adenoviral vectors decreased severity of insulitis
in STZ-induced diabetic rats, while it prolonged allograft
longevity and increased its function [24]. The increase we
observed in the level of DcR1 expression may also reflect a
defensive strategy. This is because the infiltrating leukocytes
are also known to express the TRAIL ligand themselves,
which is thought to be one of the apoptotic ligands used
by these cells to promote apoptosis in the beta cells. It was
shown by many groups before including ours that elevated
decoy receptor levels on the cell surface might provide
resistance to TRAIL. So, this elevation detected in DcR1 levels
on the pancreatic beta cells may be an initial yet eventually
inadequate eﬀort to resist the apoptotic eﬀect of TRAIL
expressed by the infiltrating lymphocytes.
DcR2 and DR5 levels were generally expressed at con-
siderable amounts in the islets in STZ-applied, as well as
CY-applied NOD mice throughout diabetes development
(Figure 7). Although both agents seemed to cause an increase
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in the expression levels of these markers, the diﬀerences in
the expression levels were not significant compared to day
0 values. A statistically significant increase in DR5 levels
in particular may have been expected, as STZ is known to
increase p53 levels, which in turn elevates the DR5 death
receptor expression [25, 26].
TRAIL ligand expression significantly decreased in CY-
injected NOD mice islets (Figure 5). CY is known to be an
immune suppressor agent. It is reported to be eﬀective on
especially the CD4+CD25+ regulator T cells (Tregs). Treg
cells suppress CD8+ T-cell population in normal conditions.
However, a high level of apoptosis was reported in Tregs
isolated from CY-applied mice, with their ability to suppress
CD8+ T-cells lost [27]. Brode et al. then detected Tregs as the
target of CY, after they specifically identified these cells with
the natural Treg marker Foxp3 [19]. The significant decrease
in our study in the level of TRAIL may be meaningful in this
regard, as TRAIL is known to be an important component of
the immune system, and lack of TRAIL leads to a faster T1D
development. In support with this, spontaneous diabetes in
NOD mice did not lead to a decrease in Treg cells [28]. The
same study claimed that spontaneous diabetes development
could not be accounted to a qualitative or quantitative
decrease in the regulator T cells, but rather to alterations
in the frequency and function of the pathogenic T cells.
Thus, CY seems to both suppress Treg cells and decrease
TRAIL expression in pancreatic islets, both of which can be
accounted for accelerated diabetes development.
The TRAIL ligand and receptor expression profiles
obtained in the acinar cells tend to strengthen the specificity
of the eﬀects of the two diﬀerent diabetes-accelerating agents
on the islets and somewhat in the acinar cells. As well
accepted, STZ is taken up by the beta cells through GLUT2
receptors, which are known as beta-cell-specific glucose
transporter molecules. We discussed above that in the
pancreatic islets, where beta cells are the most prevalent cell
type, we observed significant increases in DcR1 and TRAIL
levels after a temporary yet significant decrease between days
2 and 4 of STZ application for TRAIL (Figures 3 and 4) and
that expressions of the two other receptors (DcR2 and DR5)
were in contrast not altered significantly (Figure 5). Since the
GLUT2 receptor expression is specific to beta cells and thus
not found in the acinars, the eﬀect of STZ on the acinar cells
(gradual increase in TRAIL ligand and receptor expressions
throughout the disease course) may have appeared as a result
of the stress experienced by these cells in response to a toxic
agent introduced to their environment, but not taken up
inside, and also by the eﬀect of advanced disease. CY, on
the other hand, may have a suppressive eﬀect on TRAIL
also, besides the T regulatory cells. This diﬀerential eﬀect
by CY seems to be confirmed on acinar cells also, where
TRAIL expression was kept at minimum throughout the
CY-accelerated disease. TRAIL is an important component
of the immune system that is thought to be expressed
as a protective measure by the pancreatic islets against
the infiltrating lymphocytes. While all the TRAIL receptor
expressions generally increased in the acinar cells following
CY application, with the increase in DcR1 and DcR2 being
statistically significant (P < 0.05), none of the TRAIL
receptor expressions displayed any significant alteration in
the beta islets. This seems to support a still diﬀerential eﬀect
by CY on the islets and the acinar cells.
Various diﬀerent mice strains may be utilized as controls
in studies on NOD mice, depending on the nature of the
study and the related hypothesis. NOR mice are described
by the producer Jackson Lab as insulitis-resistant and
diabetes-free strains. While reported to still exhibit periph-
eral T-lymphocyte accumulation and defective peritoneal
macrophage responses characteristic of NOD mice, they are
defined as useful for examining the role of non-MHC genes
in development of diabetes. While STZ application at a dose
of 150mg/kg provided diabetes development in NOD mice
starting from day 4 and did not present undesired premature
toxicity, the same dose rather unexpectedly caused the death
of 80% of the NOR mice at day 7 due to a rapid rise in blood
glucose levels which resulted in severe disease manifestation
(Figure 7). This severe eﬀect exerted by STZ application
on a mice strain known as diabetes resistant may be due
to a somewhat higher toxicity of the agent on these mice,
presumably through a higher exposition by a yet unknown
mechanism. STZ is an antibiotic produced by Streptomyces
achromogenes and exerts its cytotoxic eﬀect mainly by nitric
oxide formation and alkylation of DNA [16]. It is known
as a glucose analogue accumulating selectively in pancreatic
beta cells via GLUT2 receptor [29]. Possible higher GLUT2
receptor composition in NOR mice may be the underlying
mechanism, which is currently investigated by our group. CY,
on the other hand, produced no cytotoxic/diabetic eﬀects on
NOR mice. This supports the notion that diabetes induction
by CY requires a pathological background such as insulitis,
which was evident in NOD mice [15]. As NOR mice could
not serve as controls for the STZ group, expression levels
obtained at day 0 before agent applications were used as
basic references for comparing STZ- versus CY-mediated
alterations.
Our results also implicate that while T1D models are
appropriate for wide use in the related research, diﬀerences
in the disease-causing mechanisms of diﬀerent agents should
be taken into consideration. Other significant components
of the immune system than TRAIL are highly likely to be
aﬀected distinctly in response to diﬀerent agents. Further
studies on the subject with wider experimental and control
groups and perhaps on alternative animal models as well
will contribute to the clearance of the above discussed
implications.
5. Conclusions
UsingNODmice, we found that TRAIL andDcR1 expression
levels are diﬀerentially influenced in the pancreatic islets
in STZ- versus CY-accelerated T1D. Elevated levels of both
markers detected in STZ-accelerated disease in the islets
may indicate a defense mechanism against the infiltrating
lymphocytes. On the other hand, the contrary reduction in
TRAIL expression observed following CY application might
be a part of the disease-causingmechanism of CY, in addition
to the well-proved suppressive eﬀect of this agent on the T
regulatory cells.
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